HopeAI Joins Mayo Clinic Platform to Advance Drug Development

HopeAI, which specializes in AI for accelerating new drug development, has joined the Mayo Clinic Platform Accelerate program. The partnership gives HopeAI access to Mayo Clinic’s real-world data platform, enabling more efficient and precise clinical trial design.

Bringing a new drug to market typically requires over a decade and costs billions in R&D, with clinical trials accounting for about 70% of the time and expense. Despite this investment, roughly 90% of drug candidates fail before reaching patients, delaying access to treatments for conditions such as cancer, heart disease, and rare disorders.

HopeAI applies AI-driven analytics and statistical modeling to real-world medical data to help pharmaceutical companies design trials faster, identify suitable patient populations, and improve the reliability of trial outcomes. The company’s solutions aim to reduce the high failure rate of clinical trials and bring promising therapies to patients sooner.

Through the Mayo Clinic collaboration, HopeAI joins a small group of companies with direct access to Mayo’s clinical expertise and unique datasets. One of its key innovations, developed in partnership with HemOnc.org, is a leading cancer treatment knowledge platform. This AI tool generates evidence-based recommendations for clinicians and trial designers, identifies optimal patient cohorts, and reduces costly trial delays, says the company.

HopeAI has already secured contracts with two of the world’s Top 10 pharmaceutical companies and several biotechnology firms, indicating strong demand for its technology and commercial growth potential.

The Mayo Clinic Platform partnership represents a significant milestone for HopeAI, positioning the company at the intersection of AI, big data, and precision medicine. With an addressable market valued in the hundreds of billions annually, the company’s AI-accelerated clinical trial approach could have a direct impact on both R&D efficiency and patient outcomes.